Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.18
NVS's Cash to Debt is ranked lower than
83% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. NVS: 0.18 )
Ranked among companies with meaningful Cash to Debt only.
NVS' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 1.23 Max: N/A
Current: 0.18
Equity to Asset 0.59
NVS's Equity to Asset is ranked lower than
56% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVS: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
NVS' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.59 Max: 0.65
Current: 0.59
0.51
0.65
Interest Coverage 13.69
NVS's Interest Coverage is ranked lower than
72% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 123.58 vs. NVS: 13.69 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 14.35  Med: 17.39 Max: 30.91
Current: 13.69
14.35
30.91
F-Score: 5
Z-Score: 2.43
M-Score: -2.24
WACC vs ROIC
8.81%
8.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.80
NVS's Operating margin (%) is ranked higher than
78% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.82 vs. NVS: 17.80 )
Ranked among companies with meaningful Operating margin (%) only.
NVS' s Operating margin (%) Range Over the Past 10 Years
Min: 17.81  Med: 21.41 Max: 22.35
Current: 17.8
17.81
22.35
Net-margin (%) 35.49
NVS's Net-margin (%) is ranked higher than
96% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.45 vs. NVS: 35.49 )
Ranked among companies with meaningful Net-margin (%) only.
NVS' s Net-margin (%) Range Over the Past 10 Years
Min: 15.06  Med: 19.02 Max: 31.38
Current: 35.49
15.06
31.38
ROE (%) 23.52
NVS's ROE (%) is ranked higher than
87% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NVS: 23.52 )
Ranked among companies with meaningful ROE (%) only.
NVS' s ROE (%) Range Over the Past 10 Years
Min: 12.6  Med: 15.32 Max: 25.73
Current: 23.52
12.6
25.73
ROA (%) 13.53
NVS's ROA (%) is ranked higher than
85% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.67 vs. NVS: 13.53 )
Ranked among companies with meaningful ROA (%) only.
NVS' s ROA (%) Range Over the Past 10 Years
Min: 7.21  Med: 8.97 Max: 16.18
Current: 13.53
7.21
16.18
ROC (Joel Greenblatt) (%) 47.20
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.76 vs. NVS: 47.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 43.77  Med: 61.00 Max: 81.52
Current: 47.2
43.77
81.52
Revenue Growth (3Y)(%) -2.10
NVS's Revenue Growth (3Y)(%) is ranked lower than
74% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NVS: -2.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.9  Med: 4.80 Max: 73.5
Current: -2.1
-3.9
73.5
EBITDA Growth (3Y)(%) 6.10
NVS's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVS: 6.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.7  Med: 1.95 Max: 82.8
Current: 6.1
-7.7
82.8
EPS Growth (3Y)(%) 6.70
NVS's EPS Growth (3Y)(%) is ranked higher than
51% of the 487 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. NVS: 6.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.1  Med: 5.10 Max: 82
Current: 6.7
-7.1
82
» NVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NVS Guru Trades in Q1 2015

Jim Simons 1,227,898 sh (+42.65%)
Mario Gabelli 9,840 sh (+2.61%)
Manning & Napier Advisors, Inc 361,795 sh (+0.87%)
PRIMECAP Management 22,176,613 sh (+0.04%)
Kahn Brothers 30,968 sh (unchged)
Pioneer Investments 82,942 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
John Buckingham Sold Out
HOTCHKIS & WILEY Sold Out
Lee Ainslie Sold Out
Ken Fisher 5,990,224 sh (-0.29%)
Dodge & Cox 50,032,795 sh (-0.58%)
Tweedy Browne 260,217 sh (-2.19%)
Mairs and Power 4,080 sh (-4.67%)
RS Investment Management 2,825 sh (-5.83%)
Murray Stahl 27,550 sh (-6.19%)
John Hussman 150,000 sh (-8.54%)
Sarah Ketterer 222,652 sh (-33.79%)
» More
Q2 2015

NVS Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 1,286,303 sh (+255.53%)
Sarah Ketterer 236,714 sh (+6.32%)
Ken Fisher 6,054,640 sh (+1.08%)
Pioneer Investments 83,144 sh (+0.24%)
First Eagle Investment 12,848 sh (unchged)
Mairs and Power 4,080 sh (unchged)
RS Investment Management 2,825 sh (unchged)
PRIMECAP Management 22,137,858 sh (-0.17%)
Murray Stahl 27,350 sh (-0.73%)
Tweedy Browne 254,217 sh (-2.31%)
Jim Simons 1,186,598 sh (-3.36%)
Dodge & Cox 47,970,345 sh (-4.12%)
Kahn Brothers 28,143 sh (-9.12%)
Mario Gabelli 8,330 sh (-15.35%)
John Hussman 100,000 sh (-33.33%)
» More
Q3 2015

NVS Guru Trades in Q3 2015

Manning & Napier Advisors, Inc 2,780,106 sh (+116.13%)
Jim Simons 1,682,398 sh (+41.78%)
Sarah Ketterer 262,666 sh (+10.96%)
Murray Stahl 28,750 sh (+5.12%)
Kahn Brothers 28,543 sh (+1.42%)
Ken Fisher 6,132,211 sh (+1.28%)
Mairs and Power 4,080 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
RS Investment Management 2,825 sh (unchged)
Pioneer Investments Sold Out
Tweedy Browne 249,022 sh (-2.04%)
Dodge & Cox 45,723,035 sh (-4.68%)
PRIMECAP Management 20,815,508 sh (-5.97%)
Mario Gabelli 7,540 sh (-9.48%)
John Hussman 50,000 sh (-50.00%)
» More
Q4 2015

NVS Guru Trades in Q4 2015

Ken Fisher 6,188,893 sh (+0.92%)
John Hussman Sold Out
Mario Gabelli 7,390 sh (-1.99%)
Tweedy Browne 242,201 sh (-2.74%)
Kahn Brothers 27,643 sh (-3.15%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Novartis AG

Guru Stocks at 52-Week Lows: NVS, WMT, IBM, AXP, CHU Stocks that have recently reached their historical low prices
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 9.90
NVS's P/E(ttm) is ranked higher than
90% of the 753 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.84 vs. NVS: 9.90 )
Ranked among companies with meaningful P/E(ttm) only.
NVS' s P/E(ttm) Range Over the Past 10 Years
Min: 5.69  Med: 16.00 Max: 25.7
Current: 9.9
5.69
25.7
Forward P/E 13.19
NVS's Forward P/E is ranked higher than
96% of the 417 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.22 vs. NVS: 13.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.70
NVS's PE(NRI) is ranked higher than
64% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.10 vs. NVS: 21.70 )
Ranked among companies with meaningful PE(NRI) only.
NVS' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.22 Max: 28.24
Current: 21.7
10.63
28.24
P/B 2.23
NVS's P/B is ranked higher than
55% of the 935 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. NVS: 2.23 )
Ranked among companies with meaningful P/B only.
NVS' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.52 Max: 4.14
Current: 2.23
1.69
4.14
P/S 3.48
NVS's P/S is ranked higher than
81% of the 936 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. NVS: 3.48 )
Ranked among companies with meaningful P/S only.
NVS' s P/S Range Over the Past 10 Years
Min: 1.89  Med: 3.26 Max: 5.01
Current: 3.48
1.89
5.01
PFCF 18.87
NVS's PFCF is ranked higher than
70% of the 450 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.49 vs. NVS: 18.87 )
Ranked among companies with meaningful PFCF only.
NVS' s PFCF Range Over the Past 10 Years
Min: 7.04  Med: 16.91 Max: 26.71
Current: 18.87
7.04
26.71
POCF 14.02
NVS's POCF is ranked higher than
72% of the 611 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.10 vs. NVS: 14.02 )
Ranked among companies with meaningful POCF only.
NVS' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.16 Max: 19.28
Current: 14.02
5.77
19.28
EV-to-EBIT 18.36
NVS's EV-to-EBIT is ranked higher than
51% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.36 vs. NVS: 18.36 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.35 Max: 24.2
Current: 18.36
8.5
24.2
EV-to-EBITDA 17.32
NVS's EV-to-EBITDA is ranked lower than
57% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.09 vs. NVS: 17.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 14.65 Max: 22.9
Current: 17.32
8.2
22.9
Shiller P/E 14.45
NVS's Shiller P/E is ranked higher than
89% of the 165 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.30 vs. NVS: 14.45 )
Ranked among companies with meaningful Shiller P/E only.
NVS' s Shiller P/E Range Over the Past 10 Years
Min: 9.75  Med: 13.88 Max: 21.48
Current: 14.45
9.75
21.48
Current Ratio 0.85
NVS's Current Ratio is ranked lower than
92% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. NVS: 0.85 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.41 Max: 2.83
Current: 0.85
0.84
2.83
Quick Ratio 0.62
NVS's Quick Ratio is ranked lower than
90% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. NVS: 0.62 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.16 Max: 2.48
Current: 0.62
0.62
2.48
Days Inventory 133.36
NVS's Days Inventory is ranked lower than
58% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.46 vs. NVS: 133.36 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.85  Med: 160.85 Max: 183.42
Current: 133.36
117.85
183.42
Days Sales Outstanding 60.81
NVS's Days Sales Outstanding is ranked higher than
62% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.01 vs. NVS: 60.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 64.81 Max: 70.59
Current: 60.81
56.31
70.59
Days Payable 121.99
NVS's Days Payable is ranked higher than
73% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. NVS: 121.99 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 111.18 Max: 135.35
Current: 121.99
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.65
NVS's Dividend Yield is ranked higher than
89% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. NVS: 3.65 )
Ranked among companies with meaningful Dividend Yield only.
NVS' s Dividend Yield Range Over the Past 10 Years
Min: 1.47  Med: 3.16 Max: 5.11
Current: 3.65
1.47
5.11
Dividend Payout 0.93
NVS's Dividend Payout is ranked higher than
67% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NVS: 0.93 )
Ranked among companies with meaningful Dividend Payout only.
NVS' s Dividend Payout Range Over the Past 10 Years
Min: 0.51  Med: 1.53 Max: 2.73
Current: 0.93
0.51
2.73
Dividend Growth (3y) 6.80
NVS's Dividend Growth (3y) is ranked higher than
51% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. NVS: 6.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 7.45 Max: 18.5
Current: 6.8
0
18.5
Forward Dividend Yield 3.78
NVS's Forward Dividend Yield is ranked higher than
84% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVS: 3.78 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.10
NVS's Yield on cost (5-Year) is ranked higher than
90% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.86 vs. NVS: 5.10 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.05  Med: 4.41 Max: 7.13
Current: 5.1
2.05
7.13
3-Year Average Share Buyback Ratio -0.20
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. NVS: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.2  Med: 0.90 Max: 41.9
Current: -0.2
-2.2
41.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.70
NVS's Price/Tangible Book is ranked lower than
91% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. NVS: 14.70 )
Ranked among companies with meaningful Price/Tangible Book only.
NVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.16  Med: 4.13 Max: 94.26
Current: 14.7
0.16
94.26
Price/Projected FCF 1.12
NVS's Price/Projected FCF is ranked higher than
84% of the 498 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. NVS: 1.12 )
Ranked among companies with meaningful Price/Projected FCF only.
NVS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.68  Med: 1.06 Max: 1.89
Current: 1.12
0.68
1.89
Price/Median PS Value 1.09
NVS's Price/Median PS Value is ranked higher than
54% of the 851 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. NVS: 1.09 )
Ranked among companies with meaningful Price/Median PS Value only.
NVS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.14 Max: 1.77
Current: 1.09
0.64
1.77
Price/Graham Number 4.00
NVS's Price/Graham Number is ranked lower than
79% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. NVS: 4.00 )
Ranked among companies with meaningful Price/Graham Number only.
NVS' s Price/Graham Number Range Over the Past 10 Years
Min: 0.43  Med: 1.94 Max: 8.31
Current: 4
0.43
8.31
Earnings Yield (Greenblatt) (%) 5.40
NVS's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NVS: 5.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.1  Med: 6.50 Max: 11.8
Current: 5.4
4.1
11.8
Forward Rate of Return (Yacktman) (%) 2.37
NVS's Forward Rate of Return (Yacktman) (%) is ranked lower than
62% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.77 vs. NVS: 2.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.5  Med: 6.60 Max: 79.4
Current: 2.37
-1.5
79.4

More Statistics

Revenue(Mil) $50387
EPS $ 7.28
Beta0.67
Short Percentage of Float0.24%
52-Week Range $71.90 - 106.84
Shares Outstanding(Mil)2373.89

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 50,681 53,147 60,083
EPS($) 5.00 5.53 6.91
EPS without NRI($) 5.00 5.53 6.91

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, ABT » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includesmedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Valeant's Share Price Continues to Decline Feb 05 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
Guru Stocks at 52-Week Lows Jan 26 2016 
Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows Jan 11 2016 
Berkshire Hathaway, China Mobile, Novartis, Oracle, PetroChina Near 52-Week Lows Jan 04 2016 
Guru Stocks at 52-Week Lows: NVS, WMT, IBM, AXP, CHU Nov 01 2015 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Valeant Pharmaceuticals' New Female Drug Aug 20 2015 
Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
Bill Frels' Stocks With Growing Yields Jun 27 2015 

More From Other Websites
Publicis Reports Higher-Than-Expected Sales Growth Feb 11 2016
Novartis And the Future Of Drug Pricing Feb 10 2016
Story Behind the Charts - Featured Research on Johnson Controls, Novartis, Vulcan Materials, and... Feb 10 2016
3 Big Wins Healthcare Companies Are Doing To Contain Costs Feb 10 2016
UPDATE 1-Novartis sets heart-drug price with two insurers based on health outcome Feb 09 2016
[$$] Novartis Reaches Entresto Pay-for-Performance Deals With Cigna, Aetna Feb 09 2016
Notable option activity in equity names Feb 09 2016
Early movers: KO, VIAB, CVS, ITC, TWTR & more Feb 09 2016
Fight Against Multiple Sclerosis Gains a Tech Ally Feb 08 2016
Novartis sets heart-drug price with two insurers based on health outcome Feb 08 2016
Elanco’s 4Q15 Performance: Eli Lilly’s Animal Health Segment Feb 08 2016
Insurer Cigna and Novartis set heart-drug price based on health outcome Feb 08 2016
After The Martin Shkreli Circus, How Can We Fix Drug Pricing? Feb 04 2016
[$$] Activist investors: hard drugs Feb 04 2016
Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact Feb 04 2016
Novartis AG Earnings Analysis: 2015 By the Numbers Feb 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK